Table 2.
Effect of doxepin and placebo on PSG sleep onset, sleep maintenance, and early morning awakening parameters
| Measure | Baseline |
Night 1 |
Night 29 |
Night 85 |
||||
|---|---|---|---|---|---|---|---|---|
| Mean | (SD) | Mean | (SD) | Mean | (SD) | Mean | (SD) | |
| WASO (min) | ||||||||
| Placebo | 119.5 | (37.7) | 108.9 | (46.0) | 104.6 | (53.5) | 109.2 | (50.8) |
| DXP 1 mg | 120.1 | (35.0) | 91.8** | (47.1) | 96.4 | (45.3) | 97.0* | (44.2) |
| DXP 3 mg | 117.9 | (28.2) | 74.5*** | (37.9) | 84.3*** | (40.9) | 75.7*** | (37.6) |
| TST (min) | ||||||||
| Placebo | 320.6 | (40.3) | 339.7 | (54.4) | 345.0 | (59.1) | 343.7 | (57.7) |
| DXP 1 mg | 322.4 | (39.9) | 359.1* | (53.1) | 344.4 | (55.1) | 360.5* | (47.2) |
| DXP 3 mg | 326.9 | (33.2) | 382.9*** | (44.2) | 363.9* | (54.0) | 373.7*** | (42.2) |
| SE %, Last Quarter | ||||||||
| Placebo | 64.7 | (17.0) | 62.1 | (24.3) | 64.7 | (24.9) | 65.0 | (25.7) |
| DXP 1 mg | 64.4 | (18.6) | 72.5** | (19.4) | 68.2 | (22.5) | 69.4 | (23.3) |
| DXP 3 mg | 65.0 | (15.3) | 76.6*** | (16.7) | 75.7*** | (18.6) | 76.1** | (17.8) |
| NAW | ||||||||
| Placebo | 13.6 | (4.8) | 13.2 | (5.5) | 12.6 | (5.0) | 11.9 | (5.3) |
| DXP 1 mg | 14.4 | (4.6) | 14.3 | (6.4) | 14.9* | (5.9) | 14.9** | (6.6) |
| DXP 3 mg | 13.3 | (4.3) | 14.0 | (6.2) | 13.3 | (5.2) | 12.9 | (5.6) |
| LPS (min) | ||||||||
| Placebo | 49.0 | (27.3) | 39.6 | (29.3) | 39.1 | (42.4) | 34.9 | (33.0) |
| DXP 1 mg | 45.4 | (25.3) | 38.8 | (29.6) | 49.2 | (51.2) | 29.0 | (26.5) |
| DXP 3 mg | 41.9 | (22.7) | 28.6 | (20.5) | 39.6 | (40.0) | 37.5 | (32.7) |
SD, standard deviation; DXP, doxepin; WASO, wake after sleep onset; TST, total sleep time; SE, sleep efficiency; WTAS, wake time after sleep; NAW, number of awakenings after sleep onset; LPS, latency to persistent sleep;
*
P < 0.05 vs placebo;
**
P < 0.01;
***
P < 0.001